Part D Drug Pricing Change Would Affect Commercial Plans, PBMs Say
The Pharmaceutical Care Management Association is arguing that CMS' plan to redefine the allowable cost for drugs will have a negative impact not only on Medicare Part D prescription plans, but on commercial plans as well
You may also be interested in...
CMS has decided to implement a new definition of "negotiated prices" under the Medicare Part D drug benefit that it believes will bring a new level of transparency to pricing in the program
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.